---
title: "Immuneering Corporation (IMRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMRX.US.md"
symbol: "IMRX.US"
name: "Immuneering Corporation"
industry: "Biotechnology"
datetime: "2026-05-20T17:04:49.814Z"
locales:
  - [en](https://longbridge.com/en/quote/IMRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMRX.US.md)
---

# Immuneering Corporation (IMRX.US)

## Company Overview

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [immuneering.com](https://immuneering.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.81 | 394 | - | - | - |
| PB | 1.53 | 147 | 7.47 | 1.87 | 1.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 2 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.09 |
| Highest Target | 30.00 |
| Lowest Target | 11.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IMRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IMRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IMRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IMRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**